Commercialisation of genetic diagnostic services

Medicine, Health Care and Philosophy

Volumn 1, Issue 3, 1998, Pages 217-224

  Hoedemaekers, Rogeer ^a   ten Have, Henk ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

American Medical Association; Genetic Screening; Genetic Test; Inadequate Information; Patent Protection

Indexed keywords

ARTICLE; COMMERCIAL PHENOMENA; ECONOMICS; GENETIC SCREENING; GENETIC SERVICE; GENETICS AND REPRODUCTION; HUMAN; INFORMED CONSENT; PHILOSOPHY; RISK;

GENETICS AND REPRODUCTION;

COMMERCE; GENETIC SCREENING; GENETIC SERVICES; HUMANS; INFORMED CONSENT; PHILOSOPHY, MEDICAL; RISK;

EID: 0032227664     PISSN: 13867423     EISSN: 15728633     Source Type: Journal    
DOI: 10.1023/A:1009913008908     Document Type: Article

References (44)

1. Adler, R.A.: 1992, ‘Genome research: Fulfilling the public's expectation for knowledge and commercialisation’, Science257, pp. 908–914.
2. Advisory Committee on Genetic testing (ACGT): 1997, Code of Practice and Guidance on Human Genetic Testing Services Supplied Direct to the Public. London: Health Departments of the United Kingdom.
3. Anderson, C.: 1993, ‘Genome project goes commercial’, Science259, pp. 300–302.
4. Andrews, L.B. et al. (eds.): 1994, Assessing Genetic Risks: Implications for Health and Social Policy. Washington D.C.: Institute of Medicine, National Academy Press.
5. Anonymous: 1997, ‘Genomics wheelers and dealers’, Science275, pp. 774–775. DOI: 10.1126/science.275.5301.774
6. Beauchamp, T.L. and N.E. Bowie (eds): 1993, Ethical Theory and Business. Englewood Cliffs, New Jersey: Prentice Hall Inc.
7. Biesecker, B.B. et al.: 1993, ‘Genetic counselling for families with inherited susceptibility to breast and ovarian cancer’, Journal of the American Medical Association269, pp. 1970–1974. DOI: 10.1001/jama.269.15.1970
8. Blumenthal, D.: 1992, ‘Academic-industry relationships in the life sciences’, Journal of the American Medical Association268, pp. 3344–3349. DOI: 10.1001/jama.268.23.3344
9. Blumenthal, D. et al.: 1997, ‘Withholding research results in academic life science’, Journal of the American Medical Association227, pp. 1224–1228. DOI: 10.1001/jama.277.15.1224
10. Boatright, J.R.: 1993, Ethics and the Conduct of Business. Englewood Cliffs, New Jersey: Prentice Hall.
11. Breo, D.L.: 1993, ‘Altered fates. Counselling families with inherited breast cancer’, Journal of the American Medical Association269, pp. 2017–2022. DOI: 10.1001/jama.269.15.2017
12. Brower, V.: 1997, ‘Testing, testing.. testing?’ Nature Medicine3, pp. 131–132. DOI: 10.1038/nm0297-131
13. Bull, S.: 1996, ‘Mail order gene testing’, Bulletin of Medical Ethics(February), pp. 20–21.
14. Burke, W. et al.: 1997, ‘Recommendations for follow-up of individuals with an inherited predisposition to cancer’, Journal of the American Medical Association277, pp. 997–1003. DOI: 10.1001/jama.277.12.997
15. Clarke, A. (ed.): 1994, ‘Introduction’. In: Genetic Counselling: Practice and Principles. London: Routledge.
16. Cohen, J.: 1997, ‘The genomics gamble’, Science275, pp. 767–772. DOI: 10.1126/science.275.5301.767
17. Danish Council of Ethics: 1993, Ethics and Mapping of the Human Genome. Copenhagen: Danish Council of Ethics.
18. Dausset, J.: 1996, ‘Predictive medicine’, European Journal of Obstetrics, Gynaecology and Reproductive Biology65, pp. 29–32. DOI: 10.1016/0028-2243(95)02299-8
19. Ducor, P.: 1997, ‘Are patents and research compatible’, Nature387 (1 May), pp. 13–14.
20. Editorial: 1996, ‘Capitalising on the genome’, Nature Genetics13, pp. 1–5. DOI: 10.1038/ng0596-1
21. Eisenberg, R.S.: 1992a, ‘Genes, patents, and product development’, Science257, pp. 903–908.
22. Eisenberg, R.S.: 1992b, ‘Patent rights in the human genome project’. In: Gene Mapping: Using Law and Ethics as Guides. New York: Oxford University Press.
23. Eisenberg, R.S.: 1997, ‘Structure and function in gene patenting’, Nature Genetics15, pp. 125–130. DOI: 10.1038/ng0297-125
24. Health Council of the Netherlands, Committee DNADiagnostics: 1998, DNA-Diagnostiek, Rijswijk: Health Council (1998/11).
25. Holtzman, N.A. and M.S. Watson: 1997, Promoting Safe and Effective Genetic testing in the United States, Final Report of the Task Force on Genetic testing. Baltimore: John Hopkins University Press.
26. Holtzman, N.A. et al.: 1997, ‘Predictive genetic testing: from basic research to clinical practice’, Science278, pp. 602–604. DOI: 10.1126/science.278.5338.602
27. Hubbard, R. and E. Wald: 1993, Exploding the Gene Myth: How Genetic Information is Produced and Manipulated by Scientists, Physicians, Employers, Insurance Companies, Educators and Law Enforcers. Boston: Beacon Press.
28. Jones, R.: 1996, ‘The impact of molecular medicine on health services’, Nature Medicine2, pp. 959–960. DOI: 10.1038/nm0996-959
29. Jonson, A.R. et al.: 1996, ‘The advent of the unpatients’, Nature Medicine2, pp. 622–624. DOI: 10.1038/nm0696-622
30. Joyce, C.: 1987, ‘Genes reach the medical market’, New Scientist115 (16 July), pp. 45–49.
31. Kahn, P.: 1996, ‘Coming to grips with genes and risk’, Science274, pp. 496–498. DOI: 10.1126/science.274.5287.496
32. King, M.C., S. Roweland and S.M. Love: 1993, ‘Inherited breast and ovarian cancer. What are the risks? What are the choices?’ Journal of the American Medical Association269, pp. 1975–1980. DOI: 10.1001/jama.269.15.1975
33. Marcus, A.: 1996, ‘Owning a gene: patent pending’, Nature Medicine2, pp. 728–729. DOI: 10.1038/nm0796-728
34. Marshall, E.: 1996, ‘ELSI’s cystic fibrosis experiment’, Science274, p. 489. DOI: 10.1126/science.274.5287.489
35. Marshall, E.: 1997, ‘Is data-hoarding slowing the assault on pathogens?’ Science275, pp. 777–780. DOI: 10.1126/science.275.5301.777
36. Milunski, A.: 1992, ‘Threatened survival of academic-based genetic laboratory services’, American Journal of Human Genetics50, pp. 643–645.
37. Nuffield Council on Bioethics: 1993, Genetic Screening: Ethical Issues. London: Nuffield Council on Bioethics.
38. Roberts, L.: 1990, ‘To test or not to test?’ Science247, pp. 17–19.
39. Taupitz, J.: 1993, ‘Kommerzialisierung menschlicher Körpersubstanzen’. In: R. Damm and D. Hart (eds.), Rechtliche Regulierung von Gesundheidsrisiken. Baden-Baden: Nomos Verl. Ges., pp. 51–93.
40. Tibben, A.: 1993, What is Knowledge but Grieving? On Psychological Effects of Presymptomatic DNA-testing for Huntingdon’s Disease. Rotterdam: Universiteitsdrukkerij Erasmus.
41. Trigg, M.E. and M.R. Geier: 1992, ‘On the relationship between academic and private genetic services’, American Journal of Human Genetics51, pp. 890–891.
42. U.S. Congress, Office of Technology Assessment (OTA): 1991, Biotechnology in a Global Economy. Washington, D.C.: U.S. Government Printing Office.
43. Vallance, E.: 1995, Business Ethics at Work. Cambridge: Cambridge University Press.
44. Wilfond, B.S. and K. Nolan: 1993, ‘National policy development for the clinical application of genetic diagnostic services: lessons from cystic fibrosis’, Journal of the American Medical Association270, pp. 2948–2954. DOI: 10.1001/jama.270.24.2948